{"entity":{"id":"nct07101614","kind":"trial","name":"A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy fo","aka":[],"tldr":"A phase 2 trial of toripalimab in triple-negative breast cancer, run by Shengjing Hospital, not yet recruiting.","summary":"A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC). is a phase 2, randomised interventional study registered as NCT07101614 by Shengjing Hospital, with a registry enrolment figure of 125 participants, started 2025-09-01 and due to reach its primary completion in 2027-11-30. Interventions recorded: JS004 in combination with toripalimab and chemotherapy; Toripalimab and chemotherapy; Chemotherapy. Conditions listed: TNBC - Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"In cases of multiple pathological results, the definition of triple-negative breast cancer is based on the final molecular subtype result from the last biopsy pathology\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07101614","url":"https://clinicaltrials.gov/study/NCT07101614"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["toripalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07101614","phase":"2","setting":"An Open-label, Randomized, Multi-center, Multi-cohort Clinical Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).","sponsor":"Shengjing Hospital","enrolled":125,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07101614/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}